FIELD: pharmacology.SUBSTANCE: viral infections and diseases are selected from viral infections of Herpes simplex-1 or -2, hepatitis A, hepatitis C, SARS of coronavirus infection and disease, Epstein-Barr virus, rhinovirus infections and diseases, adenovirus infections and diseases, poliomyelitis. In the formula each identical or different R1 is selected from the group consisting of halogen, linear or branched (C1-C6)alkyl, OR； L1 is a linear or branched (C1-C6)alkylene； Q is 0, 1, 2, 3 or 4； X' is CR7； R7 is OR； N is 0, 1 or 2； P is 1, 2 or3； R3, R4, R8' andR8 each represents H； A is -C (O)-； L2 is linear or branched (C1-C6) alkylene, optionally interrupted by at least one O； R6 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, H, wherein aryl, heteroaryl, cycloalkyl is mono- or polycyclic and is optionally substituted by halogen, OR； each R, identical or different, is independently selected from H, linear or branched (C1-C6)alkyl. At that, "aryl" means an aromatic monocyclic hydrocarbon ring system of 6 carbon atoms, "cycloalkyl" means a non-aromatic, monocyclic, hydrocarbon ring of 3-10 carbon atoms； "heteroaryl" means a 5-membered aromatic mono-heterocyclic ring. The invention also relates to versions of the for preparation of compounds.EFFECT: compounds can be used to prepare a drug for treatment or prevention of cancer and metastases, viral infections and diseases, or viral infectivity, or latency mediated by ubiquitin-specific proteases activity.19 cl, 6 dwg, 4 tbl, 14 exИзобретение относится к хиназолин-4-оновым соединениям формулы (I’) или их фармацевтически приемлемым солям, обладающим свойствами ингибирования дезубихитинирующего фермента. Соединения могут найти применение для получения препарата для лечения и/или профилактики рака и метастаз, вирусных инфекций и болезней, и/или вирусной инфекционности, и/или латентности, опосредованных активностью убихитин-специфических протеаз (USP). Вирусные инфекции и болезни выбраны из вирусных и
